Nanobiotix FY2027 Earnings Forecast Lowered by HC Wainwright

Posted by Renee Jackson on Sep 30th, 2026

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) – HC Wainwright lowered their FY2027 earnings estimates for shares of Nanobiotix in a note issued to investors on Friday, September 25th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.76 for the year, down from their previous estimate of $0.84. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.51) per share.

NBTX has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Leerink Partners boosted their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Finally, Guggenheim initiated coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

View Our Latest Research Report on Nanobiotix

Nanobiotix Stock Down 3.4%

Shares of NBTX opened at $31.50 on Monday. Nanobiotix has a twelve month low of $14.78 and a twelve month high of $57.14. The firm’s 50 day moving average price is $38.51 and its two-hundred day moving average price is $37.29.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.